To validate the expression of the key enzymes of NAD metabolic pathways in psoriasis lesions, we collected skin samples from patients affected by plaque psoriasis and undergone to therapeutic treatment with the anti-IL-17A antibody, secukinumab. Here, IL17A is linked to psoriasis vulgaris.